Your browser is no longer supported. Please, upgrade your browser.
Taysha Gene Therapies, Inc.
Index- P/E- EPS (ttm)-1.74 Insider Own42.61% Shs Outstand34.52M Perf Week-12.92%
Market Cap796.13M Forward P/E- EPS next Y-3.41 Insider Trans0.00% Shs Float22.01M Perf Month12.86%
Income-60.00M PEG- EPS next Q-0.56 Inst Own43.90% Short Float6.01% Perf Quarter-27.75%
Sales- P/S- EPS this Y23.80% Inst Trans0.14% Short Ratio15.93 Perf Half Y2.74%
Book/sh7.28 P/B2.99 EPS next Y-31.70% ROA- Target Price45.10 Perf Year-
Cash/sh6.87 P/C3.17 EPS next 5Y- ROE- 52W Range18.16 - 33.35 Perf YTD-17.97%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-34.72% Beta-
Dividend %- Quick Ratio36.20 Sales past 5Y- Gross Margin- 52W Low19.88% ATR1.94
Employees38 Current Ratio36.20 Sales Q/Q- Oper. Margin- RSI (14)44.35 Volatility10.21% 9.62%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.69 Prev Close20.68
ShortableYes LT Debt/Eq0.00 EarningsMar 03 BMO Payout- Avg Volume83.09K Price21.77
Recom1.50 SMA20-7.49% SMA50-8.43% SMA200-9.33% Volume57,412 Change5.27%
Feb-24-21Initiated William Blair Outperform
Jan-05-21Initiated Oppenheimer Outperform $42
Oct-19-20Initiated Morgan Stanley Overweight $29
Oct-19-20Initiated Jefferies Buy $34
Oct-19-20Initiated Goldman Buy $31
Oct-19-20Initiated Chardan Capital Markets Buy $45
May-05-21 07:00AM  
May-04-21 07:00AM  
Apr-14-21 07:00AM  
Apr-13-21 09:54AM  
Apr-12-21 11:47AM  
Apr-05-21 07:00AM  
Mar-24-21 06:27AM  
Mar-19-21 02:20PM  
Mar-11-21 07:00AM  
Mar-09-21 07:00AM  
Mar-03-21 07:00AM  
Mar-01-21 07:00AM  
Feb-26-21 07:00AM  
Feb-16-21 07:00AM  
Feb-10-21 07:00AM  
Feb-09-21 07:00AM  
Feb-01-21 07:00AM  
Jan-26-21 07:00AM  
Jan-20-21 07:32AM  
Jan-19-21 07:00AM  
Jan-13-21 07:00AM  
Jan-04-21 07:00AM  
Dec-29-20 07:00AM  
Dec-24-20 05:22AM  
Dec-21-20 07:00AM  
Dec-17-20 04:05PM  
Dec-16-20 10:36PM  
Dec-15-20 07:00AM  
Dec-03-20 07:00AM  
Nov-24-20 07:00AM  
Nov-12-20 04:05PM  
Nov-05-20 07:00AM  
Oct-27-20 07:00AM  
Oct-14-20 07:00AM  
Oct-06-20 07:00AM  
Sep-29-20 09:25AM  
Sep-25-20 08:47AM  
Sep-24-20 10:52AM  
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; and TSHA-102 for the treatment of Rett syndrome. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments; and collaboration with Yale University to advance mini-gene payloads for an AAV gene therapy for the treatment of neurodevelopmental disorders. The company was incorporated in 2019 and is based in Dallas, Texas.